ReviewDigestive diseases and sciences2026
Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is facing a demographic shift with a growing number of older adults.Advanced age affects treatment patterns and as a result older IBD patients often face conservative treatment regimens. Complications associated with aging such as frailty, comorbidities, and polypharmacy pose challenges in management.
aimThis review critically examines the influence of aging on IBD presentation and evaluates evolving treatment frameworks in older adults. It further explores the interplay of key age-related factors and their combined impact on therapeutic decision-making, clinical outcomes, and treatment-related adverse events.
methodsStudies for this narrative review were collected from Pubmed, Embase, and Web of Science. Studies addressing IBD presentation, disease outcomes, and treatment patterns in older versus younger adults were considered. Additionally, studies investigating age-related factors such as, frailty, comorbidity, and polypharmacy on treatment tolerance were considered.
resultsDisease activity and disease-related complications do not wane in severity with advanced age. Older IBD patients face overutilization of corticosteroids and reduced use of advanced therapies despite emerging data showing that certain advanced therapies such as, vedolizumab and ustekinumab, are well tolerated in this age group. Advanced therapies are often deferred due to age. However, our review highlights that frailty, comorbidity, and polypharmacy better predict treatment tolerability than chronologic age.
conclusionIBD management should shift from age-based assumptions to risk-stratified care. Our review found thatage alone did not increase most adverse events related to advanced therapy usage. This calls for a paradigm shift in treatment approaches for older adults with IBD.
Indexed as
Identifiers
42572077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.